Type 1 Diabetes

David Maahs, MD, PhD, professor of pediatrics at Stanford University and division chief of pediatric endocrinology at Lucile Packard Children’s Hospital, talks about the Timely Interventions for Diabetes Excellence dashboard, increases in continuous glucose monitoring, and more.

The pilot 4T study showed consistent hemoglobin A1C improvement in all children with type 1 diabetes (T1D) after 1 year, underscoring the importance of early continuous glucose monitoring (CGM) following diagnosis, explained David Maahs, MD, PhD, professor of pediatrics at Stanford University and division chief of pediatric endocrinology at Lucile Packard Children’s Hospital.

In a review of adults with type 1 diabetes (T1D), having a body mass index (BMI) <18.5 kg/m2 increased the risk of all-cause mortality by 3.4 times compared with normal BMI.

Individuals with type 1 diabetes (T1D) had brain atrophy patterns equivalent to a brain age about 6 years older than their actual age.

The study also showed that the measurement of HbA1c—which serves as an indicator of clinical assessment—sharply drops in the late teenage years among individuals with type 1 diabetes (T1D).

Having at least 2 episodes of severe hypoglycemia that required hospitalization was found to be a major predictor for time to death in individuals with type 1 diabetes (T1D).

David Maahs, MD, PhD, professor of pediatrics at Stanford University and division chief of pediatric endocrinology at Lucile Packard Children’s Hospital, highlights key points from his review on pediatric diabetes technology and therapy.

The study identified 3 themes related to diabetes self-care in patients who have type 1 diabetes (T1D), including emotional stress and anxiety and concerns regarding the COVID-19 pandemic.

This form of reinforcement learning was also shown to correct for control scenarios like irregular meal timing and compression errors.

Previous research has shown household food insecurity is linked with poor dietary intake, but research specific to those with diabetes has been sparse.

Young patients with type 1 diabetes (T1D) have significant social, physical, and emotional development challenges that occur before age 8.

New research suggests that racial residential segregation is associated with glycemic control among Black youth with type 1 diabetes.

The MiniMed 780G system has been approved for children aged 7 years and up with type 1 diabetes (T1D), according to Medtronic.

Although children with type 1 diabetes (T1D) are slightly more likely to experience long-term educational underachievement than their peers without T1D, those who also have a psychiatric disorder have significantly lower odds of achieving educational milestones.

Research showed the risk of progression to type 1 diabetes (T1D) was nearly 70% lower among children with high iron intake compared with children with moderate iron intake.

Researchers also found correlations between contrast sensitivity function and age, HbA1c, and type 1 diabetes (T1D) duration under different lighting conditions.

A recent analysis suggests that cardiovascular and socioeconomic factors explain one‐quarter of the racial and ethnic differences in arterial stiffness of youth with type 1 diabetes.

Data from the Finnish Pediatric Diabetes Register revealed a 16% increase in type 1 diabetes (T1D) incidence among Finnish children during the first 18 months of the COVID-19 pandemic.

Differentiating type 1 and type 2 diabetes care is a major issue that needs better understanding, said Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine

Research showed that screening 10-year-old adolescents who are at high risk of type 1 diabetes (T1D) for islet autoantibodies could predict future development of T1D.

It's harder for younger children to deal with the complexities of managing type 1 diabetes (T1D), so a delayed diagnosis even by a few years is a big deal, said Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine.

Young children using the t:slim X2 insulin pump with Control-IQ Technology system maintained target glucose levels for 3 hours longer than children using an insulin pump or daily injections with a continuous glucose monitor.

There is clearly an important role for teplizumab to treat type 1 diabetes (T1D) right now, said Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine.

Researchers found that treatment modality was associated with the proportion of youths with type 1 diabetes (T1D) achieving recommended clinical targets.

Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine, talks about some insurers' requirement for patients to have a first-degree relative with type 1 diabetes to qualify for coverage of teplizumab.

Research found that patients with acute myocardial infarction (AMI) have worse in-hospital clinical outcomes if they also have diabetes, especially type 1.

A trial enrolling 97 children newly diagnosed with type 1 diabetes did not meet the primary endpoint of preservation of insulin production by beta cells, but it did show a significant decrease in fasting and clinically relevant reduced serum glucagon.

The glycemia risk index (GRI) showed that pediatric patients and those receiving continuous subcutaneous insulin infusion had higher overall component of hypoglycemia than adults and those receiving multiple doses of insulin.

Data showed that 64% of adults without any type of diabetes had overweight or obesity, compared with 62% of adults with type 1 diabetes (T1D) and 86% with type 2 diabetes between 2016 and 2021.

Interventions in 9 studies were linked with varying effects on glycated hemoglobin, type 1 diabetes (T1D) management adherence, self-management behaviors, and parent-child teamwork in T1D management.